Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...

Novo Nordisk A/S NVO has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug ...

(Bloomberg) -- Novo Nordisk A/S shares plunged the most since December after another disappointment for the drugmaker’s next-generation shot CagriSema. The medicine helped patients with diabetes ...

compared to 3.1% for those taking a placebo. Shares sank to their lowest point in over a year after the release of the first Phase 3 trial results for CagriSema in December. Novo Nordisk's (NVO ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making versions of one of its GLP-1 agonist drugs. The latest attempt focuses ...

Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial. The Danish ...

Novo Nordisk shares fell after the pharmaceutical ... 15.7% of their weight in a late stage trial. Shares were down 8.1% in afternoon European trade. CagriSema is a two-drug combination that ...

An experimental obesity drug from Novo Nordisk resulted in 15.7% weight ... CagriSema patients achieved 15.7% weight loss, compared to 3.1% with the placebo. Nearly 90% of CagriSema patients ...